Advanced in WT1-Related Wilms Tumor Syndromes

Dr. Andrew H. Kellum

Hematology Oncology | Hematology | Oncology
961 South Gloster Street, 
Tupelo, MS 
Accepting New Patients
Offers Telehealth
Advanced in WT1-Related Wilms Tumor Syndromes
961 South Gloster Street, 
Tupelo, MS 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Andrew Kellum is a Hematologist Oncology specialist and a Hematologist in Tupelo, Mississippi. Dr. Kellum is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Large-Cell Immunoblastic Lymphoma, Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, Thrombocytopenia, and Bone Marrow Aspiration. Dr. Kellum is currently accepting new patients.

His clinical research consists of co-authoring 10 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in MS
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO

Locations

961 South Gloster Street, Tupelo, MS 38801

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinoma, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinoma, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
Enrollment Status: Completed
Publish Date: March 17, 2025
Intervention Type: Drug
Study Drugs: RRx-001, Cisplatin, Etoposide, Carboplatin, Irinotecan, Vinorelbine, Doxil, Gemcitabine, Taxane, Paclitaxel, Nab-Paclitaxel, Pemetrexed
Study Phase: Phase 2
A Randomized Phase III Trial of OSE2101 Compared With Chemotherapy (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Advanced Non-Small Cell Lung Cancer With Progressive Disease After Immune Checkpoint Inhibitors
A Randomized Phase III Trial of OSE2101 Compared With Chemotherapy (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Advanced Non-Small Cell Lung Cancer With Progressive Disease After Immune Checkpoint Inhibitors
Enrollment Status: Terminated
Publish Date: February 02, 2024
Intervention Type: Drug, Biological
Study Drugs: OSE2101, Docetaxel, Pemetrexed
Study Phase: Phase 3
A Randomized Controlled, Open Label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1+GEM vs GEM Alone in Patients With Measurable Locally Advanced/Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment
A Randomized Controlled, Open Label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1+GEM vs GEM Alone in Patients With Measurable Locally Advanced/Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment
Enrollment Status: Completed
Publish Date: May 06, 2023
Intervention Type: Drug
Study Drugs: EndoTAG-1, Gemcitabine
Study Phase: Phase 3
Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin
Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin
Enrollment Status: Completed
Publish Date: August 21, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 3 Less Clinical Trials

10 Total Publications

DNA polymerase κ participates in early S-phase DNA replication in human cells.
DNA polymerase κ participates in early S-phase DNA replication in human cells.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: July 01, 2024
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Muhammad M. Mirza
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Muhammad M. Mirza
Hematology Oncology | Hematology | Oncology

Baptist Memorial Hospital Union County, Inc.

200 Hwy 30 W, 
New Albany, MS 
 (25.2 miles away)
601-534-7631
Languages Spoken:
English, Hindi, Urdu
See accepted insurances
Accepting New Patients

Muhammad Mirza is a Hematologist Oncology specialist and a Hematologist in New Albany, Mississippi. Dr. Mirza is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are WT1-Related Wilms Tumor Syndromes, Clear Cell Sarcoma, Inflammatory Breast Cancer, and Paget Disease of the Breast. Dr. Mirza is currently accepting new patients.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. John C. Allen
Hematology Oncology | Hematology | Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. John C. Allen
Hematology Oncology | Hematology | Oncology

Baptist Memorial Hospital Union County, Inc.

200 Hwy 30 W, 
New Albany, MS 
 (25.2 miles away)
601-534-7631
Languages Spoken:
English
See accepted insurances
Accepting New Patients

John Allen is a Hematologist Oncology specialist and a Hematologist in New Albany, Mississippi. Dr. Allen is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Childhood Iron Deficiency Anemia, Angiosarcoma, Familial Colorectal Cancer, and Familial Pancreatic Cancer. Dr. Allen is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Julian B. Hill
Hematology Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Julian B. Hill
Hematology Oncology
961 South Gloster Street, 
Tupelo, MS 
 (0.1 miles away)
662-844-9166
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Julian Hill is a Hematologist Oncology provider in Tupelo, Mississippi. Dr. Hill is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Inflammatory Breast Cancer, Gastroesophageal Junction Cancer, Paget Disease of the Breast, Small Cell Lung Cancer (SCLC), and Bone Marrow Aspiration. Dr. Hill is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kellum's expertise for a condition
ConditionClose
    View All 42 Distinguished Conditions
    View All 73 Advanced Conditions
    View All 122 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile